| Bolt Biotherapeutics is a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. Co. develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Co.'s preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. We show 3 historical shares outstanding datapoints in our BOLT shares outstanding history coverage, used to compute BOLT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing BOLT market cap history over the course of time is important for investors
interested in comparing BOLT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of BOLT versus a peer is one thing; comparing
BOLT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like BOLT can fluctuate over the course of history.
With this page we aim to empower investors researching BOLT by allowing them to research the BOLT market cap history.